Study #2017-0031
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation after Autologous Stem Cell Transplantation in Patients with High-Risk Classical Hodgkin Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Brentuximab Vedotin, Nivolumab
Description
This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and brentuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study phase:
Phase II
Physician name:
Yago Nieto
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-227-7897
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.